ERBB3 and thyroid cancer: Among MAPK/ERK pathway-related genetic alterations, BRAFV600E mutation is the most common in PTCs.2 However, unlike melanoma, which is known as another kind of BRAFV600E mutation dominated malignancy, patients diagnosed with BRAFV600E-mutated thyroid cancers seldom benefit from BRAFV600E specific small-molecule inhibitors because of the existence of HER3 feedback activation.3 Thus, it is pressing to develop an effective therapeutic strategy for this type of thyroid cancer.